Guidance: Drug formulary dose cap overrides those set at a regimen level

In iQemo there is a hierarchy of control settings, so that those made at regimen level will override those set at a formulary level. This Hierarchy is present for nearly all features where the drug formulary level is the top level, which the regimen level then overrides. Within the regimen itself the regimen level is the top level, however the template level sits below that. The template overrides the regimen level. Finally within the template there is the drug level. The drug level overrides the template level. So, at each more-specific level the settings will override those set at the previous, less-specific level.

Dose caping

The one exception is dose capping. This logic is in place with the intention of aligning drug doses as defined by the SmPC for the drug. However users need to be aware that a hazard exists when, if the intention is to limit a drug by setting a cap at the regimen level, this will be overridden if a higher dose cap is set at the formulary level. The harm would be that a patient could receive a higher dose than intended. Applying the two-step verification as part of the regimen build process will mitigate this risk. A future iteration of iQemo will revisit the logic likely to remove formulary level controls for dose capping.